Skip to main content
Clinical Trials/ITMCTR2000003763
ITMCTR2000003763
Not yet recruiting
Phase 1

Clinical Study on Electroacupuncture Treatment of Nausea and Vomiting Caused by Chemotherapy of Head and Neck Tumor

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Head and neck tumors
Sponsor
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • (1\) Patients who are diagnosed as head and neck malignant tumor by histopathology and need to receive chemotherapy;
  • (2\) The age range is 18\-80 years old, regardless of gender;
  • (3\) The physical status of the patient should have a Karnofsky score \>\= 70 points;
  • (4\) Patients receiving chemotherapy containing cisplatin;
  • (5\) For multiple chemotherapy patients, the same patient is included only once:
  • (6\) Inpatients;
  • (7\) Sign informed consent, willing to cooperate with treatment, and obey random grouping.

Exclusion Criteria

  • (1\) Those who suffer from nausea and vomiting caused by mechanical risk factors such as vestibular dysfunction, metabolic imbalance, digestive system tumors, and digestive tract obstruction;
  • (2\) Tumor patients with central nervous system involvement such as intracranial metastasis;
  • (3\) Concurrent radiotherapy and chemotherapy;
  • (4\) Those who have inflammation, scars or trauma at the electroacupuncture operation site, or have a serious systemic infection that cannot be controlled;
  • (5\) Accompanied by severe complications, or severely abnormal heart function, liver and kidney function (AST, ALT, TBIL \>\= 3 times the normal value, BUN, Cr \>\= 2 times the normal value);
  • (6\) Those who cannot cooperate with opioids, a history of mental illness, or language and communication disorders;
  • (7\) Pregnant and lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials